Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Time for Preparation and Administration of Denosumab and Pamidronate
NCT02101164Phase 4Withdrawn
- Sponsor
- Amgen
- Start
- Nov 2014
- Primary completion
- Nov 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 4 trial of denosumab in metastatic bone disease (MBD), sponsored by Amgen. Planned start Nov 2014; status: withdrawn.
02
Drugs
denosumab
03
Conditions
metastatic bone disease (MBD)
Beyond the preview
Go deeper on NCT02101164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02101164.